期刊:C&EN archives [American Chemical Society] 日期:2006-10-09卷期号:84 (41): 24-25
标识
DOI:10.1021/cen-v084n041.p024
摘要
THE PHARMACEUTICAL INDUSTRY'S declining productivity, and its penchant for "me-too" products, has led many industry observers to wonder whether big companies have permanently lost their innovative edge to biotech firms. There is a perception that big pharma has become too unwieldy to act swiftly, take risks, and encourage the kind of open exchange among scientists that is generally associated with the success of smaller firms. In recent years, AstraZeneca has been among the most scrutinized of the drug majors, taking heat from consumer groups over the value and pricing of newer products while also experiencing several major disappointments with its new drug pipeline. But following a shift in its top management, the London-based company is starting to reverse that image. AstraZeneca is trying to prove the naysayers wrong by tweaking the way it does research to create a culture that is more reactive and innovative. The operations at the company's ...